Analysts Have Conflicting Sentiments on These Healthcare Companies: Palisade Bio (PALI) and Moderna (MRNA)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Palisade Bio (PALI) and Moderna (MRNA).
End of Quarter Sale - 50% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Palisade Bio (PALI)
In a report released today, Naz Rahman from Maxim Group reiterated a Buy rating on Palisade Bio, with a price target of $8.00. The company’s shares closed last Tuesday at $1.75, close to its 52-week low of $0.65.
According to TipRanks.com, Rahman has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Palisade Bio has an analyst consensus of Strong Buy, with a price target consensus of $10.67, a 502.8% upside from current levels. In a report issued on March 26, H.C. Wainwright also initiated coverage with a Buy rating on the stock with a $7.00 price target.
See today’s best-performing stocks on TipRanks >>
Moderna (MRNA)
In a report released yesterday, Salveen Richter from Goldman Sachs maintained a Hold rating on Moderna, with a price target of $41.00. The company’s shares closed last Tuesday at $50.80, close to its 52-week low of $29.25.
According to TipRanks.com, Richter is a 5-star analyst with an average return of
Currently, the analyst consensus on Moderna is a Hold with an average price target of $37.67, implying a -23.2% downside from current levels. In a report issued on March 16, Bernstein also maintained a Hold rating on the stock with a $45.00 price target.
Read More on PALI:
